Kommentar
Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions
JAMA · 19.05.2026 · 335 (19) · 1656
DOI: 10.1001/jama.2026.2123 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA, erschienen am 19.05.2026. Verfasst von Samantha Anderer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Anderer, S. (2026). Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions. JAMA, 335(19), 1656. https://doi.org/10.1001/jama.2026.2123
Vancouver
Anderer S. Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions. JAMA. 2026;335(19):1656. doi:10.1001/jama.2026.2123
BibTeX
@article{Anderer2026,
author = {Anderer, Samantha},
title = {Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions},
journal = {JAMA},
year = {2026},
volume = {335},
number = {19},
pages = {1656},
doi = {10.1001/jama.2026.2123}
}
EUVIMED